Centers for Medicare & Medicaid Services issues preliminary payment rate determination for Immunovia’s IMMray PanCan-d test
LUND, SWEDEN – Immunovia AB (Nasdaq Stockholm: IMMNOV) announced, that the Centers for Medicare & Medicaid Services (CMS) published a preliminary payment determination implying a price of $897 for the IMMray PanCan-d test. CMS is a federal agency within the United States Department of Health and Human Services that provides health coverage to more than 100 million people in the U.S. CMS sets the basis for payment for lab tests through the clinical lab free schedule (CLFS). CMS agreed with the recommendation made by the Clinical Diagnostic Laboratory Tests (CDLT) Advisory Panel to